Evidence map›Paper›PMID 29071198›Full record

ReviewNanotheranostics2017

Be Active or Not: the Relative Contribution of Active and Passive Tumor Targeting of Nanomaterials.

Rui Li, Ke Zheng, Cai Yuan, Zhuo Chen, Mingdong Huang

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nanotheranostics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 111 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Emerging 2D Nanomaterials for Biomedical Applications.Materials today (Kidlington, England) · 2021
    Article
  17. Review
  18. Review
  19. Review
  20. Therapeutics targeting the fibrinolytic system.Experimental & molecular medicine · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Rui LiKey Laboratory of Animal Immunology of the Ministry of Agriculture, Henan Provincial Key Laboratory of Animal Immunology, Henan Academy of Agricultural Sciences, Zhengzhou, Henan, 450002, China.
Ke ZhengFuzhou University, Fuzhou, Fujian, 350116, China.
Cai YuanFuzhou University, Fuzhou, Fujian, 350116, China.
Zhuo ChenFujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, Fujian, 350002, China.
Mingdong HuangFuzhou University, Fuzhou, Fujian, 350116, China.
Fujian Institute of Research on the Structure of Matter · CNFuzhou University · CNHenan Academy of Agricultural Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant tumor (cancer) remains as one of the deadliest diseases throughout the world, despite its overall mortality drops. Nanomaterials (NMs) have been widely studied as diagnostic and/or therapeutic agents for tumors. A feature of NMs, compared to small molecules, is that NMs can be concentrated passively in tumors through enhanced permeability and retention (EPR) effect. In the meantime, NMs can be engineered to target toward tumor specific markers in an active manner,

Indexed as

amino-terminal fragment.enhanced permeability and retention effectnanomaterialnanoparticlereceptor-mediated tumor targetingurokinase-type plasminogen activator receptor

Identifiers

PMID29071198
PMCPMC5646738
OpenAlexW2735353052

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.